Baz Okkes, Kara Necip, Bozkurt Ercument, Ozgurhan Engin Bilge, Agca Alper, Yuksel Kemal, Ozpinar Yavuz, Demirok Ahmet
Department of Ophthalmology, Beyoglu Eye Research and Education Hospital, Istanbul, Turkey.
Int J Ophthalmol. 2013 Jun 18;6(3):356-61. doi: 10.3980/j.issn.2222-3959.2013.03.19. Print 2013.
To evaluate the results of three photorefractive keratectomy (PRK) procedures in the treatment of astigmatism.
In this retrospective comparative case series, 89 eyes of 50 patients who underwent PRK treatment for astigmatism were enrolled. The patients were divided into 3 groups based on the PRK procedure: Group 1: PRK without mitomycin-C (MMC) application, Group 2: PRK with MMC application, and Group 3: Trans-Photorefractive Keratectomy (T-PRK). The efficacy, safety, predictability, and complications of treatment were assessed at 1, 3 and 6 months after the treatment.
At postoperative 6 months, the percentage of postoperative uncorrected visual acuity (UCVA) of 20/20 or better was 55.6% (20 eyes) in group 1, 75% (15 eyes) in group 2, and 75.8% (25 eyes) in group 3 (P=0.144). The percentage of postoperative best corrected visual acuity (BCVA) of unchanged or gained ≥1 lines was 80.6% (29 eyes) in group 1, 70% (14 eyes) in group 2, and 90.9% (30 eyes) in group 3 (P=0.151). The percentage of postoperative BCVA of lost ≥2 lines was 11.1% (4 eyes) in group 1, 20% (4 eyes) in group 2, and 6.1% (2 eyes) in group 3. The mean manifest refractive spherical equivalent (MRSE) and mean cylindrical refraction were not significantly different among the each groups (P>0.05). At postoperative 6 months, the percentage of MRSE of within ±0.50 D was 100% (36 eyes) in Group 1, 100% (20 eyes) in Group 2, and 93.9% (31 eyes) in Group 3. At the each follow-up period, there was no significant difference in number of eyes with haze and mean haze score(P>0.05).
The study showed that PRK without MMC, PRK with MMC and T-PRK appears to have similar effectiveness, safety and predictability in the treatment of astigmatism. The incidence of haze was also similar between the three groups.
评估三种准分子激光角膜切削术(PRK)治疗散光的效果。
在这个回顾性比较病例系列中,纳入了50例接受PRK治疗散光的患者的89只眼。根据PRK手术方式将患者分为3组:第1组:未应用丝裂霉素-C(MMC)的PRK;第2组:应用MMC的PRK;第3组:经上皮准分子激光角膜切削术(T-PRK)。在治疗后1、3和6个月评估治疗的有效性、安全性、可预测性和并发症。
术后6个月,第1组术后裸眼视力(UCVA)达到20/20或更好的比例为55.6%(20只眼),第2组为75%(15只眼),第3组为75.8%(25只眼)(P = 0.144)。第1组术后最佳矫正视力(BCVA)不变或提高≥1行的比例为80.6%(29只眼),第2组为70%(14只眼),第3组为90.9%(30只眼)(P = 0.151)。第1组术后BCVA下降≥2行的比例为11.1%(4只眼),第2组为20%(4只眼),第3组为6.1%(2只眼)。各组间平均显屈光球镜等效度(MRSE)和平均柱镜度数差异无统计学意义(P>0.05)。术后6个月,第1组MRSE在±0.50 D以内的比例为100%(36只眼),第2组为100%(20只眼),第3组为93.9%(31只眼)。在每个随访期,有 haze的眼数和平均haze评分差异无统计学意义(P>0.05)。
研究表明,未应用MMC的PRK、应用MMC的PRK和T-PRK在治疗散光方面似乎具有相似的有效性、安全性和可预测性。三组间haze的发生率也相似。